  |
Market Research in the Healthcare Field with Expertise in Medical Imaging and Radioisotopes
Bio-Tech Systems, Inc. - 4167 West Pinecrest Circle - Las Vegas, Nevada 89121 phone: (702) 456-7608 - fax: (702) 456-2189
THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS |
|
BIO-TECH SYSTEMS INC. announces the publication of: BIO-TECH Report #270, The U.S. Market for Diagnostic Radiopharmaceuticals The Diagnostic Radiopharmaceutical Report Includes:
There are good prospects for continued growth of myocardial perfusion procedures notwithstanding the expiration of the Cardiolite patent in 2008. Although there will be some decline in revenue, procedure volume will continue to grow. This will help companies offering the perfusion agents as well as radiopharmacies providing the services. New molecular imaging and therapeutic modalities are being developed based on apoptosis, angiogenesis and PLE (Phospho-Lipid Ether) tumor targeting that will employ both SPECT and PET imaging. This will include new oncology products for diagnosing and monitoring cellular response to therapy. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness. Therapeutic radiopharmaceuticals will also employ molecular imaging to assess biodistribution and aid in developing patient specific dosimetry necessary for optimizing dosage and evaluating patient response to therapy. The prospects for growth of PET procedures is also covered, with analysis of expanding opportunities for FDG imaging as well as new specialized PET agents for oncology and neurology. The recent introduction of SPECT-CT imaging should increase the specificity of diagnosis, particularly with new targeted agents for oncology and neurology. This will bring nuclear medicine closer to the mainstream of radiology imaging, where the referral base is very large, as it has with PET-CT. This stimulus to nuclear medicine will encourage more investment from biopharmaceutical companies and venture groups that will ultimately promote future market growth. Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects U.S. sales of diagnostic radiopharmaceuticals reached $1.93 billion in 2007 and are expected to rise to $4.06 billion by 2014. Radiopharmaceutical sales grew 9.0% in 2007, recovering from a temporary slowdown the previous year. However, growth should resume in the range of 11% 13% per year as new products are introduced for cardiology and oncology. Continued growth of PET imaging and sales of FDG will also contribute favorably. Sales of nuclear cardiology products will continue to bolster the radiopharmaceutical market, with high utilization of nuclear perfusion studies coupled with advanced pharmacologic stress agents and introduction of new products for imaging myocardial infarction and congestive heart failure. Therefore, nuclear cardiology sales of $1.29 billion in 2007 will increase to $2.10 billion by 2014. FDG sales will increase from $398 million in 2007 to $1,358 million by 2014. FDG distribution will continue to improve, allowing more widespread use of PET in community hospitals. With reimbursement stabilizing and procedure volume increasing, PET should become more profitable for providers as well as suppliers of FDG. In addition, new PET radiopharmaceuticals in the pipeline for specialized applications should add to these sales. Market growth should also benefit from higher prices for many of the new products. More biopharmaceutical products for SPECT imaging will incorporate combined molecular imaging and therapy platforms with broad applicability to many different types of cancer, expanding the range of nuclear procedures. Availability of SPECT-CT will also add an important dimension to these new agents, aiding in image interpretation. This technical influx will help all segments of nuclear medicine, expanding the platform for molecular imaging. One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field. Please follow one of the links below, or on the left, to find out more information about BIO-TECH Report #270. If you are interested in purchasing BIO-TECH Report #270, please follow this link to our Online Order Form. To download a detailed Table of Contents (TOC) for BIO-TECH Report #270, please click on one of the two links below. The documents are a Microsoft Word 97-2000 file and an Adobe Acrobat 6 PDF file.  Download TOC in MS Word format (111KB) Download TOC in Adobe PDF format (69KB) |
Back to Top| Report Contents | Partial List of Exhibits |
| Report #270 Home Page |
|
Download Report #270 Table of Contents: BTSI270.doc
-OR-
BTSI270.pdf
|
Send
this page to a friend
Breaking Market News | Orders | News Releases | Contact Us
Report #340 | Report #330 | Report #290 | Report #260 | Report #230 | Top